



UK Health
Security
Agency

UK Standards for Microbiology Investigations

Investigation of faecal specimens for *Clostridioides difficile*



Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on [the UK SMI website](#). UK SMIs are developed, reviewed and revised by various working groups which are overseen by a [steering committee](#).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

UK SMIs are produced in association with:



Displayed logos correct as of December 2024

Contents

UK Standards for Microbiology Investigations	1
Acknowledgments	2
Contents	3
Amendment table	4
1 General information	5
2 Scientific information.....	5
3 Scope of document	5
4 Introduction	7
5 <i>C. difficile</i> infection diagnostic tests	9
6 Technical information and/or limitations	12
7 Safety considerations	12
8 Pre-laboratory processes (pre-analytical stage)	13
9 Laboratory processes (analytical stage).....	15
10 Post-laboratory processes (post analytical stage)	17
11 Mandatory Reporting of <i>C. difficile</i> infection.....	22
12 Antimicrobial Susceptibility Testing	23
13 Referral to reference or specialist testing laboratories	24
Appendix: <i>C. difficile</i> culture and Identification	25
References.....	28

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Any alterations to this document should be controlled in accordance with the local document control process.

Amendment number/date	x/dd.mm.yy
Issue number discarded	
Insert issue number	
Anticipated next review date*	dd.mm.yy
Section(s) involved	Amendment

*Reviews can be extended up to 5 years where appropriate

1 General information

[View general information](#) related to UK SMIs.

2 Scientific information

[View scientific information](#) related to UK SMIs.

3 Scope of document

This UK SMI describes the investigation of faeces for *Clostridioides difficile*, the laboratory interpretation of results, and the reporting of *C. difficile* infection (CDI) cases for the purposes of mandatory surveillance.

The diagnosis of *C. difficile* infection (CDI) is based on both clinical presentation and laboratory testing (1-5). No single test is reliable as a stand-alone test for the laboratory diagnosis of *C. difficile* infection (2-7). This document describes why a two-stage testing approach is required followed by a third test where the primary test is positive and the secondary test is negative (2-5,8,9). A sensitive *C. difficile* glutamate dehydrogenase (GDH) immunoassay or Nucleic Acid Amplification Test (NAAT) is recommended as a primary test followed by a highly specific toxin A and B immunoassay (2-5,8,9).

For the management and treatment of *C. difficile* infections, clinicians should assess the patient's current clinical condition and refer to the relevant guidance e.g., the National Institute for Health and Care Excellence (NICE), the Healthcare Infection Society (HIS) and the Scottish Antimicrobial Prescribing Guidance (SAPG) guidelines (10-12).

Please refer to [UK SMI S 07: Gastroenteritis](#) and [UK SMI ID 8 - Identification of Clostridium species](#) for additional information.

This UK SMI should be used in conjunction with other UK SMIs.

Definitions

Key terms	Definition
Diarrhoea	<p>Stools of a loose or liquid consistency (typically classed as 5 to 7 on the Bristol Stool Form Scale) occurring more frequently than is normal for the individual. Usually at least ≥ 3 instances in a 24-hour period; however, the consistency of stools is a more important indicator than the frequency (13-15).</p> <p>Diarrhoea may be associated with symptoms such as abdominal cramps, nausea, malaise, vomiting, fever and dehydration.</p> <p>Note: In high-risk individuals and settings where transmission of infection is a concern, strict reliance on 3 or more episodes of diarrhoea within 24 hours to instigate testing and pre-emptive patient isolation may be inappropriate. Therefore, some flexibility is required to ensure that unexplained diarrhoea is appropriately investigated and managed (2).</p>

Colonisation/Carriage	Both terms are used interchangeably and generally mean the detection of <i>C. difficile</i> in the absence of <i>C. difficile</i> infection symptoms. Colonisation with toxigenic strains of <i>C. difficile</i> leads to asymptomatic carriage which highlights the potential risk of transmission.
Toxigenic	<p><i>C. difficile</i> strain containing toxin genes (<i>tcdA</i> and/or <i>tcdB</i>) and are therefore capable of producing toxins that cause <i>C. difficile</i> infection.</p> <p>Note: The term toxigenic should not be used when reporting/interpreting results to avoid confusion.</p>
<i>C. difficile</i> infection	<p><u>England, Wales, and Northern Ireland:</u></p> <p>One episode of diarrhoea, defined either as stool loose enough to take the shape of a container used to sample it or as Bristol Stool Chart types 5 – 7, that is not attributable to any other cause, including medicines, and that occurs at the same time as a positive toxin assay (with or without a positive <i>C. difficile</i> culture) and/or endoscopic evidence of pseudomembranous colitis (PMC) (3,15).</p> <p><u>Scotland:</u></p> <p>A case of CDI is someone in whose stool <i>C. difficile</i> toxin has been identified at the same time as they have experienced diarrhoea not attributable to any other cause, or from whose stool <i>C. difficile</i> has been cultured at the same time as they have been diagnosed with pseudomembranous colitis (PMC) (5).</p>

4 Introduction

Clostridioides difficile infection (CDI) remains a significant health concern in the UK, with a substantial increase in CDI cases (16-19). In the 2022 - 2023 financial year, annual CDI cases in England increased by 11.3% with a rate of 27.6 infections per 100,000 population compared to the previous financial year (2021 - 2022) (16). An increase in both community and hospital-onset CDI was observed, with community-onset being disproportionately higher at 58.3% (16). The reason for the recent rise in CDI cases is unclear with no expansion of a particular *C. difficile* ribotype (16). Therefore, continued surveillance with enhanced testing is crucial to support infection prevention and control interventions for the management of the increasing incidence of CDI.

C. difficile is a Gram positive, spore forming, strictly anaerobic rod, so named because of the difficulty in original culture and characterisation (20,21). The taxonomic differences between this species and other members of the *Clostridium* genus is reflected by the change in nomenclature to *Clostridioides* (22-24). Toxigenic *C. difficile* strains produce two large, structurally similar protein toxins (A and B), which are the main virulence factors in CDI (25). *C. difficile* can colonise the colon and may cause a spectrum of disease in humans, from a self-limiting mild diarrhoea to the advanced and severe illness characterised by pseudomembranous colitis (PMC).

Transmission of *C. difficile* is via the faeco-oral route. CDI is predominantly healthcare-associated but can be isolated from soil, water, hospital and domiciliary environments as well as animal faeces, all of which can act as a reservoir for cross-infection (26). These may be a source of infection where infection prevention and control are inadequate.

4.1 Pathogenicity

The production of the enterotoxin, toxin A (TcdA), and cytotoxin, toxin B (TcdB) by *C. difficile* causes cell death (21). These toxins (type III exotoxins which glycosylate and inactivate intracellular Rho-family GTPases resulting in changes in the actin cytoskeleton) cause the characteristic mucosal damage consisting of plaque-like lesions which may, in some cases, result in the formation of pseudomembranes in the colon (21).

In strains which possess the toxin gene, toxin production is controlled by toxin regulatory genes and can occur in response to various conditions such as the presence of antibiotics or specific nutrients. Only strains that possess the pathogenic locus (PaLoc) carry the genes for the toxins A (TcdA) and B (TcdB) and can cause CDI (21). Strains that lack PaLoc do not produce these toxins and are generally non-pathogenic (i.e., non-toxigenic strains), and therefore do not cause CDI. Most pathogenic strains produce both TcdA and TcdB, however, clinically significant strains causing diarrhoea and colitis have been isolated which are TcdA negative and TcdB positive (27). Outbreaks caused by these strains have been documented and although TcdA positive and TcdB negative strains have not been recorded, it is essential to use diagnostic toxin immunoassays capable of detecting both toxins (28). Some NAATs only target either toxin A (*tcdA*) or toxin B (*tcdB*) genes. This is suitable if those that only detect toxin A genes target the conserved portion of the *tcdA* gene and not the truncated region, which is absent in *C. difficile* strains that do not produce TcdA enterotoxin.

Deletions in the toxin regulatory gene *tcdC* are associated with greater production of TcdA and TcdB as described in the hypervirulent *C. difficile* strain 027 (29,30). In addition, around one third of strains of *C. difficile* produce a binary toxin (CDT) which is not part of PaLoc and therefore may be present in the absence of TcdA and TcdB. This toxin may contribute to the severity of infection in certain hypervirulent strains, although its exact role in the pathogenesis of CDI remains unclear (31).

4.2 Risk factors and course of *C. difficile* infection

Acquisition of *C. difficile* alone does not induce CDI. Individuals may be *C. difficile* carriers (i.e., have asymptomatic colonisation) of either non-toxigenic or toxigenic strains of *C. difficile*. For asymptomatic carriage of toxigenic strains to progress to CDI, other contributing factors are often required.

C. difficile colonisation is relatively uncommon in the general population but significantly increases among hospitalised patients, particularly those treated with antibiotics. However, even when CDI is ruled out, it is worth applying infection prevention and control measures, especially when the patient has loose stools, given the carrier state and the potential for contamination of the environment with *C. difficile*.

The incidence of *C. difficile* colonisation varies in the literature, influenced by factors such as study population and epidemiological differences. Some studies report that around 2% of the general population is colonised with toxigenic *C. difficile* strains. In hospitalised patients, this rate can be as high as 7 - 25% of hospitalised patients (32-35). *C. difficile* has also been found in up to 50% of infants, who may become colonised in the first few months of life, although disease is rarely present at this age (36,37).

The main risk factor for CDI is the repeated use of broad-spectrum antibiotics that alter or distort the normal microbiota. Changes in the human gut microbiota, associated with antibiotic therapy or other treatments such as chemotherapeutic and radiotherapeutic agents permits asymptomatic colonisation by *C. difficile* (38). The over-growth of toxin-producing strains of *C. difficile* can damage the lining of the colon leading to the development of CDI.

Almost all drugs with an antibacterial spectrum of activity have been implicated causally in CDI. The most frequently implicated drugs are those which have a marked detrimental effect on the microbiota of the colon. These include broad spectrum beta lactams, cephalosporins, clindamycin and fluoroquinolones (39).

Other risk factors for the development of CDI include immunosuppression, advanced age, patients undergoing general surgery and underlying co-morbidities such as chronic renal disease, inflammatory bowel disease and cancer (40-43). The importance of age can be demonstrated by figures from the UKHSA annual summary report on *C. difficile* infections which show that the highest proportion of cases (in which age was reported) were from patients > 65 years old (16).

The spectrum of *C. difficile* disease ranges from asymptomatic carriage, through a self-limiting mild diarrhoea to the advanced and severe illness characterised by pseudomembranous colitis (44). Severe colitis, with or without pseudomembranes, can result in partial or complete ileus or toxic megacolon, perforation, and death (21). If present, pseudomembranous colitis is seen on endoscopy. Endoscopy is not routinely indicated but is diagnostic in, for example, suspected cases of 'silent' CDI,

such as ileus, toxic megacolon or pseudomembranous colitis without diarrhoea such that submission of a stool specimen for laboratory testing is impossible (44). It may also be useful when CDI is suspected but laboratory testing for CDI consistently yields negative results. In such circumstances, rectal swabs, peripheral white cell count (WCC), serum creatinine and abdominal imaging such as CT (computerised tomography) scanning can also aid diagnosis and management (45).

4.3 Treatment and management

Treatment and management guidelines for CDI are produced in the United Kingdom by the National Institute for Health and Care Excellence (NICE), the Healthcare Infection Society (HIS), and the Scottish Antimicrobial Prescribing Group (SAPG) (10-12). Outside of the United Kingdom, they are produced by societies such as the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Infectious Disease Society of America (IDSA) (46-48).

Scotland follow their respective National Infection, Prevention and Control Manuals, which England and Wales have also adopted (49,50). While Northern Ireland adhere to their own National Infection, Prevention and Control Manuals (51).

In the UK, the overall 30-day case fatality rate of CDI remains relatively high at around 13% with a CDI mortality rate of 3.8 deaths per 100,000 population (2022-2023 FY) (52). Recurrence of CDI occurs in around 15-25% of primary cases, which rises to 65% of cases having a recurrence after a third or subsequent episode (47,53-55).

5 *C. difficile* infection diagnostic tests

This section describes the tests available for CDI diagnosis. Refer to Section 9 and 10 for the order of CDI testing.

5.1 Glutamate dehydrogenase antigen detection assays

GDHs are a group of enzymes abundantly present in all bacteria, including toxigenic and non-toxigenic strains of *C. difficile*. The GDH of *C. difficile* can therefore be used as an accurate marker for the presence of *C. difficile* in faecal samples. To avoid cross-reactivity with other prokaryotic and eukaryotic GDH enzymes, relatively specific monoclonal antibodies are raised to *C. difficile*-specific GDH. GDH assays are commercially available as membrane assays and enzyme immunoassays (EIAs) and are quick to perform and comparatively inexpensive.

The GDH antigen test has a high clinical sensitivity but is less specific than *C. difficile* toxin-based assays as it detects both toxigenic and non-toxigenic strains. It is therefore useful as a primary test when used in conjunction with more specific confirmatory test(s). Same day reporting of negative samples is achievable with this method as GDH negative results do not need further testing for *C. difficile*. The role of GDH in the detection of *C. difficile* has been the focus of several studies which have recognised its effective use in a dual test approach to testing (9,56-58).

5.2 Molecular methods

NAATs, and particularly PCR assays, have been used to target *C. difficile* toxin A and B genes in faeces (59). Assays which detect *C. difficile* toxin gene(s) demonstrate the potential to produce toxins by a *C. difficile* strain in a patient's sample (60). The detection of these genes by NAAT (NAAT detected result) in a sample where no toxin proteins are detectable by toxin immunoassay is well-described. This is because, like GDH tests, the NAAT assays are more sensitive than the toxin A and B immunoassays. Also, similar to GDH assays, NAAT tests have lower clinical specificity, but results can be available within 2 hours.

In addition, there are several multiplex molecular gastrointestinal pathogen panels commercially available that include *C. difficile*. These have the advantage of being both rapid and analytically sensitive with results for gastrointestinal pathogen panels returning in less than a day (61,62). Some of these multiplex PCR assays detect not only the toxin B gene, but also other conserved genes indicative of the 'hypervirulent' strain ribotype 027, and binary toxin (63,64). Due to the lower clinical specificity of these tests for CDI, in comparison with toxin A and B immunoassays, these tests should not be used alone as a diagnostic test for *C. difficile* (7,62,65). NAAT testing, as with GDH detection, may detect asymptomatic carriage of *C. difficile* (7,65,66).

5.3 Toxin A & B antigen detection assays

There are numerous commercially available toxin A and B immunoassay tests intended to detect *C. difficile* toxins. Use of immunoassays that detect both toxins A and B is essential, as infection due to A negative but B positive strains have been recorded (27,67). *C. difficile* toxin assays are commercially available as membrane assays and well-based EIAs and are quick to perform and relatively inexpensive. As with all assays, the analytical and clinical sensitivity/specificity of these kits vary, although, in general *C. difficile* toxin immunoassays lack clinical sensitivity, if used alone, but are highly specific for CDI. For this reason, they should be used in a two-stage testing approach followed by a third test where the primary test is positive and the secondary test is negative (68-73).

5.4 Other methods

5.4.1 Cell-Cytotoxicity neutralisation assay (Cell-culture)

Although regarded as the "gold standard", use of tissue culture for the detection of *C. difficile* toxins by virtue of its cytopathic effect (CPE) (neutralisable with *C. sordellii* antitoxin), has now been surpassed by other methods. The required technical expertise, the unavailability of the antitoxin in the UK, and usually a 24 to 48-hour delay for the final result in comparison to other methods has made this method no longer viable (74).

Tissue culture, especially with vero cells, could also detect other faecal cytotoxins that are associated with diarrhoea e.g., *C. perfringens* enterotoxin although this is mitigated by the use of the neutralising antitoxin (75). CPE that is not neutralised by *C. sordellii* antitoxin may indicate that another pathogen is present. The unavailability of antitoxin in the UK, however, means this method is also not feasible for use.

5.4.2 Faecal calprotectin

Some studies have investigated faecal calprotectin (an indicator of general intestinal inflammation) as an adjunctive method to diagnose CDI. Although the sensitivity of this test is high, it lacks specificity and is therefore not recommended (76).

5.5 Identification

5.5.1 *C. difficile* culture

Refer to the Appendix for information regarding the isolation of *C. difficile*, confirmation of presumptive isolates and reporting of results.

Culture has limited clinical utility for the diagnosis of CDI due to its long turnaround time and the need for confirmatory testing. Therefore, it is more widely used by laboratories for epidemiological surveillance where typing and/or susceptibility testing is required and used as a reference method to validate newer diagnostic tests.

In Scotland laboratory culture of faeces is recommended in cases of severe disease, suspected outbreaks, in recurrent cases (> 28 days and < 56 days) and as part of the [C. difficile snapshot programme](#). In England and Northern Ireland culture may be undertaken by the CDRN. In Wales, all GDH/NAAT positive samples should be referred to the UKARU for *C. difficile* culture.

5.6 Typing of *Clostridioides difficile*

Typing of isolates of *C. difficile* is useful in the investigation of increased frequency of CDI, to determine potential transmission, as well as in cases of increased severity, complication, recurrence or death rate presumptively associated with CDI (77). Historically, many typing techniques have been used in the investigation of outbreaks of CDI. Those in recent use are exclusively DNA-based (78-80).

PCR-ribotyping in conjunction with multilocus variable-number tandem-repeat analysis (MLVA) and more recently, analysis of whole genome sequencing (WGS) data, are techniques used routinely to distinguish isolates of *C. difficile* in the UK (78).

The culture and identification of *C. difficile* is important for typing in cases of increased incidence, in outbreak situations and for general surveillance, including drug resistance and virulence determinant detection.

Pure culture or isolate of *C. difficile* is required for typing. Please refer to the appropriate UK *C. difficile* typing services in Section 13 for specific requirements.

5.6.1 PCR Ribotyping and MLVA

PCR ribotyping is an internationally recognised method for typing of *C. difficile* isolates, based on 16S-23S intergenic spacer region diversity. More than 1,100 PCR ribotypes have now been identified (81-83).

The MLVA technique offers enhanced fingerprinting of *C. difficile* isolates and can be used to determine closely related isolates (and help identify transmission) in settings where PCR-ribotyping data are insufficient (78,79).

5.6.2 Whole Genome sequencing

Whole genome sequencing allows the comparison of entire microbial genomes and has emerged as an important tool in the epidemiological study of *C. difficile*. This technique can simultaneously detect sequences that (i) encode toxin genes and other virulence factors (ii) potentially confer resistance to antibiotics, and (iii) facilitate the measurement of relatedness between *C. difficile* strains with high resolution. WGS-based typing can be undertaken using traditional, core- or whole-genome MLST (cgMLST/wgMLST). Alternatively, single-nucleotide polymorphism (SNP) typing offers ultimate discriminatory power (78). Therefore, analysis of whole genome sequence data may allow surveillance of emerging lineages with higher transmissibility and important genetic markers.

6 Technical information and/or limitations

6.1 General considerations

As with all laboratory tests, *C. difficile* assays may vary in their analytic and clinical sensitivity and specificity, with some performing particularly poorly. Therefore, it is crucial for laboratories to understand the strengths and limitations of any method they employ for detection of *C. difficile*, and its toxins.

Manufacturer's instructions should be followed and all test kits and NAAT platforms should be validated and verified prior to use.

Laboratories should also incorporate these assays within the recommended two-stage testing approach followed by a third test where the primary test is positive and the secondary test is negative (see section 8). This is because the detection of *C. difficile* by culture, GDH test or by NAAT alone has a poor specificity for the diagnosis of *C. difficile* infection. These methods do not detect toxin produced by *C. difficile* but instead detect the presence of the bacterium or the genes for toxin production (7).

Therefore, detection of *C. difficile* in an individual's faeces by one of these tests when it is used as the only method of detection does not necessarily mean that the patient has toxin-mediated *C. difficile* infection, and careful clinical correlation is required. Alternative aetiologies should be sought in such cases.

7 Safety considerations

This section covers specific safety considerations related to this UK SMI and should be read in conjunction with the general [safety considerations](#) (81-101)

7.1 Specimen Collection, Transport and Storage

Collect specimens using aseptic technique.

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

7.2 Specimen Processing

Processing of specimens should be carried out in a containment level 2 laboratory, as a minimum.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

The above guidance should be supplemented with local COSHH and risk assessments.

8 Pre-laboratory processes (pre-analytical stage)

8.1 Eligibility criteria for testing:

In all UK nations, faecal specimens that meet the testing criteria should be tested for CDI. This includes all specimens of diarrhoea* that are not attributable to an underlying condition e.g., inflammatory colitis or therapy e.g., laxatives. Also, in all UK nations screening of symptom-free patients and clearance testing is not recommended.

*Please refer to the Scope of the document and Section 8.3.1 for the definition of diarrhoea and correct specimen type, respectively.

In the UK (except Scotland) faecal specimens that meet the testing criteria should be tested for *C. difficile* from:

- Ideally, all patients aged ≥ 2 years old.

Acknowledging that resources may not allow testing of all patients ≥ 2 years old, as a minimum, the following patients should be tested:

- All hospital patients aged ≥ 2 years old.
- All community patients ≥ 65 years old.
- Community patients < 65 years old where clinically indicated, which includes but is not limited to:
 - If *C. difficile* mentioned in request clinical details
 - If the patient is recognised by the testing laboratory, microbiologists or IPC team as previously having *C. difficile*;
 - If current or prior antibiotic therapy is mentioned;
 - If a hospital admission is mentioned;
 - If residence at a care home or other community care facility is indicated by the patient address, or mentioned on the request form;
 - Immunocompromised (e.g. transplant patients, patients on chemotherapy)

- Inflammatory bowel disease (IBD; e.g. Crohn's disease or Ulcerative Colitis)
- Abdominal surgery
- Chronic renal/kidney disease (CKD);
- If clinical details indicate patient has been prescribed a proton pump inhibitor (PPI; e.g. lansoprazole, omeprazole);
- When specifically requested

Note: CDI is not confined to the groups above and may not have been considered by the requestor. Half of community CDI cases may be undetected because of absence of clinical suspicion, accounting for three times more undiagnosed adults in the community compared with hospitals in one study (102).

In Scotland, faecal specimens that meet the testing criteria should be tested for *C. difficile* in patients from:

- All patients \geq 3 years old.

Notes:

Under the mandatory surveillance programme, only confirmed CDI cases aged 15 and above need to be reported to ARHAI Scotland (5). However, it is recommended that patients aged 3 - 14 with confirmed CDI are also reported for surveillance purposes.

In Scotland, a case of CDI used for mandatory reporting is defined as someone in whose stool *C. difficile* toxin has been identified at the same time as they have experienced diarrhoea not attributable to any other cause, or from whose stool *C. difficile* has been cultured at the same time as they have been diagnosed with pseudomembranous colitis (PMC) (5).

8.2 Specimen type:

Faeces

Note: Rectal swabs may be used as an alternative to stool samples in cases where stool collection is not feasible. They can also aid in diagnosing silent CDI (paralytic ileus, toxic megacolon, or pseudomembranous colitis) without diarrhoea alongside other diagnostic methods such as colonoscopy or clinical indicators (1,4,45,103-105). However, rectal swabs should be analysed using molecular methods (4,45,103-105).

8.3 Specimen Collection

For safety considerations refer to Section 7.

Faecal samples from symptomatic patients should be taken at the earliest point *C. difficile* is expected.

A liquid specimen of 1 - 2mL is sufficient for culture and toxin detection.

Numbers and frequency of specimen collection are dependent on clinical condition of patient.

Note: It is not recommended to wait for three episodes of diarrhoea to occur prior to initiate testing in settings where transmission of infection is a concern (2).

8.3.1 Correct specimen type and method of collection

Specimens may be passed into a clean, dry, disposable bedpan or similar container and transferred into a CE marked leak proof container. The specimen is unsatisfactory if any residual soap, detergent, or disinfectant remains in the pan. Samples mixed with large amounts of urine are also unsuitable.

Ideally, the sample container should be one quarter full (to indicate the patient has diarrhoea) and the sample should take the shape of the container. Formed stools are usually unsuitable for investigation for *C. difficile*. These should be rejected with the appropriate comment appended to the report, unless specifically requested by a consultant microbiologist or equivalent.

8.4 Transport and Storage

Specimens should be transported and processed as soon as possible.

If processing is delayed, refrigeration at 4°C is preferable to storage at ambient temperature. Refrigerate for up to the time indicated in the manufacturer's recommendations if unable to process within two hours. Freezing samples at -20°C compromises faecal toxin testing (106). Therefore, it is essential to conduct toxin tests before long-term freezing and thawing of samples for subsequent culturing and typing (3,5,106)

All *C. difficile* toxin immunoassay positive faecal samples should be kept refrigerated or frozen, for culture and subsequent typing, which may be required in certain situations e.g., an outbreak or as part of surveillance (107).

Where capacity allows, storage of toxin immunoassay negative but NAAT positive samples may be useful, as transmission may only be apparent when these strains are typed. It is not necessary to keep the whole specimen, a small aliquot Eppendorf will suffice (108). The duration of storage needs to be determined locally but should allow for appropriate outbreak investigation, where necessary (99).

9 Laboratory processes (analytical stage)

9.1 *C. difficile* infection diagnostic procedure

A two-stage testing approach with a third test where the primary test is positive and secondary test is negative is required (2-5).

This consists of a GDH immunoassay or NAAT followed by a toxin A and B immunoassay (2,4,8). Where GDH and toxin immunoassay testing are initially conducted and a discordant result obtained, i.e., one result is positive and the other negative, a NAAT should be performed as a reflex test to distinguish between toxigenic and non-toxigenic samples (2,4,8). The requirements for further *C. difficile* culture and identification vary by nation, refer to Section 5.5.1 *C. difficile* culture.

In Scotland laboratory culture of faeces is recommended in cases of severe disease, suspected outbreaks and as part of [C. difficile snapshot programme](#) (5).

In England and Northern Ireland culture may be undertaken by the CDRN.

In Wales, all GDH/NAAT positive samples should be referred to the UKARU for *C. difficile* culture.

UNDER CONSULTATION

10 Post-laboratory processes (post analytical stage)

10.1 Interpreting and reporting laboratory results

No single test is reliable as a stand-alone test for diagnosing *C. difficile* infection. A GDH, single-plex NAAT or gastrointestinal panel multiplex NAAT positive test is not sufficient for the diagnosis of CDI (see sections 5 and 6). A two-stage testing approach followed by a third test where the primary test is positive and the secondary test is negative (see footnote*) is advised for the diagnosis of CDI as outlined in section 9.

Results require clinical correlation, particularly for toxin immunoassay negative or discordant results. These should be discussed with the clinical team to ensure accurate interpretation and appropriate patient management. Appropriate IPC measures should be applied to patients with a positive immunoassay or NAAT.

Tables 1 and 2 address a testing algorithm that incorporates reflex testing. Table 3 addresses a scenario where all tests are conducted simultaneously.

Table 1: Interpretation and reporting GDH immunoassay followed by Toxin A and B immunoassay (followed by a 3rd test if required, see footnote*)

	1st Assay	2nd Assay	3rd Assay (if required*)	Results	Result interpretive comment	Clinical comments for inclusion on laboratory reports
	GDH immunoassay	Toxin A and B immunoassay	NAAT (toxin DNA detection)			
1	Negative	Not required	Not required	<i>Clostridioides difficile</i> Not detected	No laboratory evidence of <i>Clostridioides difficile</i> infection	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
2	Positive	Positive	Not required	<i>Clostridioides difficile</i> Detected	Laboratory evidence of <i>Clostridioides difficile</i> infection.	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.

Investigation of faecal specimens for *Clostridioides difficile*

3	Positive	Negative	Negative	<i>Clostridioides difficile</i> Not detected	No laboratory evidence of <i>Clostridioides difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
4	Positive	Negative	Positive	<i>Clostridioides difficile</i> DNA Detected.	May indicate <i>Clostridioides difficile</i> infection requiring treatment.	Please clinically evaluate the patient and liaise with microbiology for advice. Refer to local management guidelines for IPC precautions to reduce risk of further transmission.
5	Positive	Negative	Invalid/inhibitory***	Invalid/inhibitory result	-	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission. Please send a repeat sample.
6	Positive	Negative	Test not available in-house and referred to external laboratory*(see footnotes)	Interim report	Specimen referred for confirmatory testing	Please clinically evaluate the patient and liaise with microbiology for advice. Refer to local management guidelines for IPC precautions to reduce risk of further transmission.

Table 2: Interpretation and reporting NAAT followed by Toxin A and B immunoassay.

	1st Assay	2nd Assay	Results	Result interpretation	Clinical comments for inclusion on laboratory reports
	NAAT (toxin DNA detection)	Toxin A and B immunoassay			
1	Negative	Not required	<i>Clostridioides difficile</i> not detected	No laboratory evidence of <i>Clostridioides difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
2	Positive	Positive	<i>Clostridioides difficile</i> DETECTED	Laboratory evidence of <i>Clostridioides difficile</i> infection.	Consistent with <i>Clostridioides difficile</i> infection. Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.
3	Positive	Negative	<i>Clostridioides difficile</i> DNA Detected.	May indicate <i>Clostridioides difficile</i> infection requiring treatment.	Please clinically evaluate the patient and liaise with microbiology for advice. Refer to local management guidelines for IPC precautions to reduce risk of further transmission.
4	Invalid/inhibitory	Not required	Invalid/inhibitory result***	-	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission. Please send a repeat sample.

Table 3: Interpretation and reporting GDH immunoassay performed at the same time as Toxin A and B immunoassay (followed by a 3rd test if required, see footnote*).

	Combined Assays		3 rd Assay (if required*)	Results	Result interpretation	Clinical comments for inclusion on laboratory reports
	GDH immunoassay	Toxin A and B immunoassay	NAAT (toxin DNA detection)			
1	Negative	Negative	Not required	<i>Clostridioides difficile</i> Not detected	No laboratory evidence of <i>Clostridioides difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
2	Positive	Positive	Not required	<i>Clostridioides difficile</i> Detected	Laboratory evidence of <i>Clostridioides difficile</i> infection.	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.
3	Positive	Negative	Negative	<i>Clostridioides difficile</i> Not detected	No laboratory evidence of <i>Clostridioides difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
4	Positive	Negative	Positive	<i>Clostridioides difficile</i> DNA Detected.	May indicate <i>Clostridioides difficile</i> infection requiring treatment.	Please clinically evaluate the patient and liaise with microbiology for advice. Refer to local management guidelines for IPC precautions to reduce risk of further transmission.

Investigation of faecal specimens for *Clostridioides difficile*

5	Negative	Positive** (see footnotes. Report as invalid toxin result)	Negative	<i>Clostridioides difficile</i> Not detected	No laboratory evidence of <i>Clostridioides difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
6	Negative	Positive	Positive	<i>Clostridioides difficile</i> Detected	Laboratory evidence of <i>Clostridioides difficile</i> infection.	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.
7	Positive	Negative	Invalid/inhibitory***	Invalid/inhibitory result	-	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission. Please send a repeat sample.

Tables footnotes:

* UK SMI recommends the use of a NAAT for all samples where the primary test is positive and the secondary test is negative. Where NAAT is not available in-house, an interim report should be issued, and specimens should be referred to a laboratory capable of testing using a *C. difficile* NAAT. It should be recognised that not performing an in-house NAAT severely compromises the clinical utility of laboratory results.

** Where GDH and toxin A and B immunoassay testing is undertaken simultaneously, a toxin A and B immunoassay positive result in the absence of GDH and NAAT positivity should be reported as 'invalid' as there is an extremely high probability that it represents a false positive toxin A and B immunoassay result.

*** Platforms may use different terminology, such as 'invalid' instead of 'inhibitory'.

10.2 Repeat Testing of Specimens

In the event of negative test results for CDI, where patient symptoms persist, re-testing is recommended as it is known that false negatives can occur (109)

In the event of positive test results for CDI, subsequent testing is not necessary for test of cure as *C. difficile* may persist in the bowel without causing disease (110). However, repeat testing may be required in the following cases:

- 1) If a patient recovers from CDI related diarrhoea and then has a recurrence of symptoms (this could indicate recurrence of CDI – either relapse or re-infection)
- 2) If patient's symptoms persist after completing a treatment course (this could indicate refractory CDI)
- 3) If patient develops other symptoms consistent with *C. difficile* infection (this could indicate severe or severe-complicated CDI or refractory CDI)

Notes:

Laboratories should adhere to a strict clinical testing criteria for repeat testing within 28 days and interpret results with caution within 1 – 2 months of the CDI diagnosis. This is crucial to avoid CDI misdiagnosis due to prolonged shedding of *C. difficile* toxin which can vary, stopping either before or beyond 28 days (111,112).

For CDI symptoms, diarrhoea should meet the specific definition provided in the document for repeat testing. For definitions of key terms used in the document, refer to the scope of the document.

For repeat testing, a new faecal sample should be tested for CDI using the algorithm, regardless of whether the repeat test is within 28 days of a positive toxin test.

11 Mandatory Reporting of *C. difficile* infection

In the UK there is a mandatory reporting scheme for CDI. The public health agencies within the UK, namely UKHSA (England), the Public Health Agency (Northern Ireland), Public Health Scotland and Public Health Wales capture cases of CDI that meet specific criteria. Please ensure that these cases are entered onto the relevant data capture system, where required. Details can be found in the following links:

England, Wales, and Northern Ireland:

https://hcaidcs.phe.org.uk/ContentManagement/LinksAndAnnouncements/HCAIDCS_Mandatory_Surveillance_Protocol_v4.4.pdf

Note: Welsh HCAI Surveillance Monthly Dashboard:

<https://public.tableau.com/app/profile/victoria6405/viz/WalesHCAISurveillanceMonthlyDashboard/HBMonthlyDashboard>

Scotland:

[Protocol for the Scottish Surveillance Programme for *Clostridioides difficile* infection: user manual | National Services Scotland](#)

12 Antimicrobial Susceptibility Testing

Routine susceptibility testing is not generally carried out in the UK, however CDRN, UKARU and EBIS monitor antimicrobial susceptibility of isolates of *C. difficile* submitted as part of the voluntary surveillance schemes. Continuing surveillance of susceptibility is required to detect the emergence of resistance.

Vancomycin and fidaxomicin are currently the antibiotics of choice for treatment of CDI and as the choice depends upon the clinical scenario, it is recommended that local treatment guidelines are referred to (10). Metronidazole is no longer recommended by NICE to treat *C. difficile* infection. Refer to [EUCAST](#) guidelines for information.

Prudent use of antimicrobials according to local and national protocols is recommended.

UNDER CONSULTATION

13 Referral to reference or specialist testing laboratories

If isolates are sent to reference or specialist testing laboratories for processing, ensure that the specimen is placed in the appropriate packaging and transported accordingly. Follow local regulations and instructions provided by the reference or specialist testing laboratories for sending isolates.

Contact the appropriate reference laboratory (refer to the links provided below) for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission.

[England](#)

[Wales](#)

[Scotland](#)

[Northern Ireland](#)

13.1 Referral for Outbreak Investigations

Isolates or faeces for ribotyping in connection with outbreaks should be referred to the appropriate reference laboratory. The reference laboratory should be contacted prior to sample submission, where required.

Contact details for the reference laboratories can be found at:

- The *Clostridioides difficile* Ribotyping Network (CDRN) for England and Northern Ireland – regional microbiologists:
<https://www.gov.uk/guidance/clostridium-difficile-ribotyping-network-cdrn-guide-to-services>
- The UK Anaerobe Reference Unit (UKARU) in Cardiff:
<https://phw.nhs.wales/services-and-teams/reference-laboratories-and-specialist-services/uk-anaerobe-reference-unit-ukaru/>
- The Enteric Bacterial Infections Service (EBIS); formerly known as the Scottish Salmonella, Shigella and *Clostridioides difficile* Reference Laboratory; in Glasgow: <https://www.nhs.uk/scottish-microbiology-reference-laboratories/enteric-bacterial-infections-service/>

Appendix: *C. difficile* culture and Identification

Culture

Alcohol shock method for culture of *C. difficile*

The advantage of using alcohol shock for selection of *C. difficile* is that only spores should survive this process, and it eliminates the growth of other non-sporing faecal organisms. The selective agents within the culture medium are usually based on cefoxitin and cycloserine (although others have been described), and these are usually inhibitory to most other clostridial species and other gut microbiota bacteria. The resulting growth from an active case of infection is often a pure culture of *C. difficile*.

It should be noted that the same medium from different suppliers may give different colonial appearances and the descriptions given here are not absolute.

1. Make an approximate 1:1 suspension of stool sample and 70% methanol, or 95% ethanol; in a screw capped glass bijou.
2. Mix by vortexing and leave to settle at room temperature for 30 min.
3. With a disposable pastette, inoculate two drops (approx 50 -75 µl) of the deposit to cefoxitin-cycloserine egg yolk* (CCEY) selective agar and streak for single colonies. At the same time, culture the control organisms on CCEY from their spore suspension and incubate as outlined below.
4. Incubate anaerobically at 35°C - 37°C for 48 - 72hr. Cultures may be examined after overnight incubation but should not be removed from the anaerobic workstation because sporulation is inhibited on selective media and young cultures may die on exposure to air. If using anaerobic jars, cultures must not be examined before 48 hours incubation.

* Egg-yolk supplement is optional.

Identification

Colonies of *C. difficile* can be recognised by the following characteristics:

- If using egg-yolk based agar, a lack of opacity surrounding the colonies due to non-production of lecithinase (unlike *Paraclostridium bifermentans* [previously *Clostridium bifermentans*], *C. perfringens* or *Paraclostridium sordellii* [previously *Clostridium sordellii*]). Follow individual media manufacturer's guidelines on colonial morphology.
- Green-yellow fluorescence under long-wave UV light (see below).
- Agglutination with *C. difficile* latex reagent for somatic antigen (see below).
- MALDI TOF MS identification. This should be performed after 18-24hr subculture to FAA or blood agar. Older cultures may lead to poor identification due to spore formation.
- NAAT. Use of a method with high analytical specificity is essential.

For ease of identification, it is useful to sub-culture a putative *C. difficile* colony on Fastidious Anaerobe Agar (FAA) or blood agar (BA).

Refer to individual UK SMIs for organism identification.

Examination of plates

Colonies of *C. difficile* may be smooth or rough and may vary considerably in size. Typical colonies may be seen after sub-culture of suspect colonies from selective media on FAA or BA.

Colonial Fluorescence

- Remove the test and control plates from the anaerobic workstation/jar and examine the colonies for fluorescence. Expose the colonies to long wave ultra-violet light (365 nm) in a darkened room, or light box held closely to the UV source, and view by reflection.
- UV protective goggles must be worn, where required.
- Colonies of *C. difficile* may vary in the intensity of fluorescence, but this will appear as a green-yellow or chartreuse colour. Fluorescence is poorly developed on some agar bases and is strongest on FAA. It is important to compare fluorescence of the test colonies with that of the control organisms to clarify positive and negative results. The colonial fluorescence of cultures >48 hrs old on non-selective agars will diminish due to increased sporulation.
- Mark any suspect (fluorescent) colonies on the underside of the plate with a marker pen. Sub-culture to a FAA or BA plate and incubate anaerobically for 24-48hrs.
- **Note:** Gram staining is rarely useful directly from selective agars, but from blood agar plates sub-terminal spores should be visible with most vegetative rods staining as Gram positive with some Gram variable forms in common with many other clostridial species. Routine Gram staining is not recommended.

Latex agglutination test for somatic antigen

Use *C. difficile* somatic antigen latex agglutination and follow the instructions in the kit insert.

Limitations of the test

Cross-reactions with this reagent are known to occur with:

- *P. bifementans*
- *P. sordellii*
- *T. glycolicus*

Controls

Set up controls alongside test cultures and on each new batch of medium.

Control organisms required:

- *P. bifementans*.

- *P. sordellii*.
- *C. difficile*.

Other clostridial species are commonly mistaken for *C. difficile*. These include *C. innocuum*, *T. glycolicum*, *P. bifermentans* and *P. sordellii*. However, these may be differentiated according to the criteria listed in Table 1.

Interpretation of results

Table A. Differential tests for recognition of colonies of *C. difficile*

	<i>C. difficile</i>	<i>P. bifermentans</i>	<i>P. sordellii</i>	<i>T. glycolicum</i>	<i>C. innocuum</i>
UV (Fluorescence) at 365nm	+	-	-	-	+
Latex agglutination	+	+	+	+	-
Lecithinase on Brazier's CCEY medium	-	+	+	-	-

Organisms may be further identified if this is clinically or epidemiologically indicated.

Refer to individual UK SMIs for organism identification.

Culture reporting

C. difficile isolated/not isolated.

Where *C. difficile* is confirmed - isolates of *C. difficile* submitted for typing investigations. Further report to follow.

Note: Subsequent to culture, a toxin test may be performed to determine whether or not the isolate is a toxin producing strain (58). Selective, differential agars are available on which toxin producing and non-toxin producing *C. difficile* strains can be distinguished, although care should be taken as some strains may go undetected using chromogenic media (113). As with all media, chromogenic and selective agar should be verified prior to use.

References

An explanation of the reference assessment used is available in the [scientific information section on the UK SMI website](#).

1. Tung W, Hays R. Atypical presentation of *Clostridioides difficile* pseudomembranous colitis with laboratory rejection of stool specimen. *BMJ case reports* 2019: volume 12, issue 11. doi.org/10.1136/bcr-2019-230629
2. Department of Health and Social Care. *Clostridium difficile*: updated guidance on diagnosis and reporting 2012.
3. UK Health Security Agency and Department of Health and Social Care. *Clostridioides difficile* infection: how to deal with the problem 2008.
4. Scottish Microbiology and Virology Network. Review of *Clostridioides difficile* diagnostic testing in NHS Scotland: Best practice recommendations 2024.
5. Antimicrobial Resistance and Healthcare Associated Infection Scotland. Protocol for surveillance of *Clostridioides difficile* infection- Version 5.0 2024.
6. Czepiel J and others. *Clostridium difficile* infection: review. *European Journal of Clinical Microbiology & Infectious Diseases* 2019: volume 38, issue 7, pages 1211-21. 10.1007/s10096-019-03539-6
7. Chandrabos C and others. The Diagnosis and Treatment of *Clostridium difficile* Diagnosed by Stool Polymerase Chain Reaction Does Not Alter the Clinical Course of Patients With Inflammatory Bowel Disease: A Case-Control Study. *Official journal of the American College of Gastroenterology | ACG* 2021: volume 116. 10.14309/01.ajg.0000776364.63111.fe
8. Crobach MJT and others. *European Society of Clinical Microbiology and Infectious Diseases*: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clinical Microbiology and Infection* 2016: volume 22, pages S63-S81. 10.1016/j.cmi.2016.03.010
9. Planche TD and others. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C difficile* infection. *The Lancet infectious diseases* 2013: volume 13, issue 11, pages 936-45. [https://doi.org/10.1016/S1473-3099\(13\)70200-7](https://doi.org/10.1016/S1473-3099(13)70200-7)
10. National Institute for Health and Care Excellence (NICE). *Clostridioides difficile* infection: antimicrobial prescribing 2021. <https://www.nice.org.uk/guidance/ng199>
11. Mullish BH and others. The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridioides difficile* infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Journal of Hospital Infection* 2024: volume 148, pages 189-219. 10.1016/j.jhin.2024.03.001

12. Scottish Antimicrobial Prescribing Group (SAPG). Antimicrobial management of *Clostridioides difficile* (C.diff) Infection (CDI) in adults (>18 years) 2022.
13. World Health Organisation (WHO). Diarrhoeal disease 2024.
14. World Health Organisation (WHO). The treatment of diarrhoea: A manual for physicians and other senior health workers 2005.
15. Corrigan RA and others. Usefulness of the Bristol Stool Form Chart scoring system for the laboratory processing of faecal samples in suspected *Clostridioides difficile* cases. *Journal of Hospital Infection* 2020: volume 105, issue 1, pages 95-7. 10.1016/j.jhin.2019.12.005
16. UK Health Security Agency (UKHSA). Annual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and *C. difficile* infections, up to and including financial year 2023 to 2024 2024.
17. Antimicrobial Resistance and Healthcare Associated Infection Scotland. ARHAI Scotland 2023 Annual Report 2024.
18. Hilvers E and others. *Clostridioides difficile* infection following COVID-19: A nationwide analysis using routine surveillance data in Wales. *Journal of Hospital Infection*. 10.1016/j.jhin.2024.07.011
19. Public Health Agency. *C.difficile* and *S.aureus* surveillance quarterly reports 2022-2024 2024.
20. Kuijper EJ and others. *Clostridium*, *Clostridioides*, and Other *Clostridia**. *Manual of Clinical Microbiology*,; 2023.
21. Kordus SL and others. *Clostridioides difficile* toxins: mechanisms of action and antitoxin therapeutics. *Nature Reviews Microbiology* 2022: volume 20, issue 5, pages 285-98. 10.1038/s41579-021-00660-2
22. Lawson PA and others. Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Prévot 1938. *Anaerobe* 2016: volume 40, pages 95-9. <https://doi.org/10.1016/j.anaerobe.2016.06.008>
23. Parte AC and others. List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. *International Journal of Systematic and Evolutionary Microbiology* 2020: volume 70, issue 11, pages 5607-12. <https://doi.org/10.1099/ijsem.0.004332>
24. Schoch CL and others. NCBI Taxonomy: a comprehensive update on curation, resources and tools. *Database* 2020: volume 2020. 10.1093/database/baaa062

25. Gröschel DHM, Tøye B. *Clostridium difficile* Infection. *Critical Reviews in Clinical Laboratory Sciences* 1996: volume 33, issue 3, pages 203-45. 10.3109/10408369609083061
26. Brazier JS. The epidemiology and typing of *Clostridium difficile*. *J Antimicrob Chemother* 1998: volume 41 Suppl C, pages 47-57. 10.1093/jac/41.suppl_3.47
27. Drudy D and others. Toxin A-negative, toxin B-positive *Clostridium difficile*. *Int J Infect Dis* 2007: volume 11, issue 1, pages 5-10. 10.1016/j.ijid.2006.04.003
28. She RC and others. Evaluation of enzyme immunoassays to detect *Clostridium difficile* toxin from anaerobic stool culture. *Am J Clin Pathol* 2009: volume 131, issue 1, pages 81-4. 10.1309/ajcpmm2e7vsphnpg
29. Matamouros S and others. *Clostridium difficile* toxin expression is inhibited by the novel regulator TcdC. *Molecular Microbiology* 2007: volume 64, issue 5, pages 1274-88. <https://doi.org/10.1111/j.1365-2958.2007.05739.x>
30. Wolff D and others. Rapid detection of the *Clostridium difficile* ribotype 027 tcdC gene frame shift mutation at position 117 by real-time PCR and melt curve analysis. *Eur J Clin Microbiol Infect Dis* 2009: volume 28, issue 8, pages 959-62. 10.1007/s10096-009-0731-7
31. Martínez-Meléndez A and others. An Update on *Clostridioides difficile* Binary Toxin. *Toxins* 2022: volume 14, issue 5, pages 305.
32. Aronsson B and others. Antimicrobial agents and *Clostridium difficile* in acute enteric disease: epidemiological data from Sweden, 1980-1982. *J Infect Dis* 1985: volume 151, issue 3, pages 476-81. 10.1093/infdis/151.3.476
33. Clabots CR and others. Acquisition of *Clostridium difficile* by hospitalized patients: evidence for colonized new admissions as a source of infection. *J Infect Dis* 1992: volume 166, issue 3, pages 561-7. 10.1093/infdis/166.3.561
34. Samore MH and others. *Clostridium difficile* Colonization and Diarrhea at a Tertiary Care Hospital. *Clinical Infectious Diseases* 1994: volume 18, issue 2, pages 181-7. 10.1093/clinids/18.2.181
35. Shim JK and others. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet* 1998: volume 351, issue 9103, pages 633-6. 10.1016/s0140-6736(97)08062-8
36. Wilson KH. The microecology of *Clostridium difficile*. *Clin Infect Dis* 1993: volume 16 Suppl 4, pages S214-8. 10.1093/clinids/16.supplement_4.s214
37. el-Mohandes AE and others. Prevalence and toxigenicity of *Clostridium difficile* isolates in fecal microflora of preterm infants in the intensive care nursery. *Biol Neonate* 1993: volume 63, issue 4, pages 225-9. 10.1159/000243935

38. Bignardi GE. Risk factors for *Clostridium difficile* infection. *J Hosp Infect* 1998: volume 40, issue 1, pages 1-15. 10.1016/s0195-6701(98)90019-6
39. Impallomeni M and others. Increased risk of diarrhoea caused by *Clostridium difficile* in elderly patients receiving cefotaxime. *BMJ* 1995: volume 311, issue 7016, pages 1345-6. 10.1136/bmj.311.7016.1345
40. Testore GP and others. Evidence for cross-infection in an outbreak of *Clostridium difficile*-associated diarrhoea in a surgical unit. *J Med Microbiol* 1988: volume 26, issue 2, pages 125-8. 10.1099/00222615-26-2-125
41. Kamthan AG and others. *Clostridium difficile* diarrhea induced by cancer chemotherapy. *Arch Intern Med* 1992: volume 152, issue 8, pages 1715-7.
42. Gérard M and others. Incidence and significance of *Clostridium difficile* in hospitalized cancer patients. *Eur J Clin Microbiol Infect Dis* 1988: volume 7, issue 2, pages 274-8. 10.1007/bf01963101
43. Cumming AD and others. Diarrhoea due to *Clostridium difficile* associated with antibiotic treatment in patients receiving dialysis: the role of cross infection. *Br Med J (Clin Res Ed)* 1986: volume 292, issue 6515, pages 238-9. 10.1136/bmj.292.6515.238
44. Smits WK and others. *Clostridium difficile* infection. *Nat Rev Dis Primers* 2016: volume 2, pages 16020. 10.1038/nrdp.2016.20
45. Jazmati N and others. Evaluation of the Use of Rectal Swabs for Laboratory Diagnosis of *Clostridium difficile* Infection. *Journal of Clinical Microbiology* 2018: volume 56, issue 7, pages 10.1128/jcm.00426-18. doi:10.1128/jcm.00426-18
46. van Prehn J and others. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for *Clostridioides difficile* infection in adults. *Clinical Microbiology and Infection* 2021: volume 27, pages S1-S21. <https://doi.org/10.1016/j.cmi.2021.09.038>
47. Johnson S and others. Recurrences of *Clostridium difficile* diarrhea not caused by the original infecting organism. *J Infect Dis* 1989: volume 159, issue 2, pages 340-3. 10.1093/infdis/159.2.340
48. Johnson S and others. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of *Clostridioides difficile* Infection in Adults. *Clin Infect Dis* 2021: volume 73, issue 5, pages e1029-e44. 10.1093/cid/ciab549
49. National Services Scotland. National Infection Prevention and Control Manual 2022.

50. NHS England. National infection prevention and control manual (NIPCM) for England 2022.
51. Public Health Agency (PHA). Clostridioides difficile Infection 2024.
52. UK Health Security Agency. 30 day all-cause mortality following MRSA, MSSA and Gram-negative bacteraemia and C. difficile infections: 2022 to 2023 report 2024.
53. Louie TJ and others. Fidaxomicin versus Vancomycin for *Clostridium difficile* Infection. New England Journal of Medicine 2011: volume 364, issue 5, pages 422-31. doi:10.1056/NEJMoa0910812
54. Cornely OA and others. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012: volume 12, issue 4, pages 281-9. 10.1016/S1473-3099(11)70374-7
55. Liu C and others. Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective. Antibiotics (Basel) 2023: volume 12, issue 7. 10.3390/antibiotics12071141
56. Shetty N and others. The role of glutamate dehydrogenase for the detection of *Clostridium difficile* in faecal samples: a meta-analysis. J Hosp Infect 2011: volume 77, issue 1, pages 1-6. 10.1016/j.jhin.2010.07.024
57. Goldenberg SD and others. Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic *Clostridium difficile*. J Hosp Infect 2010: volume 74, issue 1, pages 48-54. 10.1016/j.jhin.2009.08.014
58. Carroll KC. Tests for the diagnosis of *Clostridium difficile* infection: the next generation. Anaerobe 2011: volume 17, issue 4, pages 170-4. 10.1016/j.anaerobe.2011.01.002
59. Perry MD and others. Evaluation of the Luminex xTAG Gastrointestinal Pathogen Panel and the Savyon Diagnostics Gastrointestinal Infection Panel for the detection of enteric pathogens in clinical samples. Journal of medical microbiology 2014: volume 63, issue 11, pages 1419-26. <https://doi.org/10.1099/jmm.0.074773-0>
60. Perry MD and others. Impact of the introduction of nucleic acid amplification testing on Clostridioides difficile detection and ribotype distribution in Wales. Anaerobe 2021: volume 67, pages 102313. <https://doi.org/10.1016/j.anaerobe.2020.102313>
61. Ramanan P and others. Syndromic Panel-Based Testing in Clinical Microbiology. Clin Microbiol Rev 2018: volume 31, issue 1. 10.1128/cmr.00024-17

62. Hannet I and others. Multicenter evaluation of the new QIAstat Gastrointestinal Panel for the rapid syndromic testing of acute gastroenteritis. *Eur J Clin Microbiol Infect Dis* 2019: volume 38, issue 11, pages 2103-12. 10.1007/s10096-019-03646-4
63. Jia X-x and others. A rapid multiplex real-time PCR detection of toxigenic *Clostridioides difficile* directly from fecal samples. *3 Biotech* 2023: volume 13, issue 2, pages 54. 10.1007/s13205-022-03434-6
64. Kouhsari E and others. Rapid Simultaneous Molecular Stool-Based Detection of Toxigenic *Clostridioides difficile* by Quantitative TaqMan Real-Time PCR Assay. *Clinical Laboratory* 2019: volume 65, issue 4, pages 461-9-9. 10.7754/Clin.Lab.2018.180735
65. Ilges D and others. Positive impact of a diagnostic stewardship intervention on syndromic panel ordering practices and inappropriate *C. difficile* treatment. *Infection Control & Hospital Epidemiology* 2024, pages 1-6. 10.1017/ice.2024.180
66. Cotter JM and others. Impact of Multiplex Testing on the Identification of Pediatric *Clostridioides Difficile*. *The Journal of Pediatrics* 2020: volume 218, pages 157-65. 10.1016/j.jpeds.2019.11.036
67. al-Barrak A and others. An outbreak of toxin A negative, toxin B positive *Clostridium difficile*-associated diarrhea in a Canadian tertiary-care hospital. *Can Commun Dis Rep* 1999: volume 25, issue 7, pages 65-9.
68. O'Connor D and others. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2001: volume 39, issue 8, pages 2846-9. 10.1128/jcm.39.8.2846-2849.2001
69. Musher DM and others. Detection of *Clostridium difficile* Toxin: Comparison of Enzyme Immunoassay Results with Results Obtained by Cytotoxicity Assay. *Journal of Clinical Microbiology* 2007: volume 45, issue 8, pages 2737-9. doi:10.1128/jcm.00686-07
70. Turgeon DK and others. Six rapid tests for direct detection of *Clostridium difficile* and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. *J Clin Microbiol* 2003: volume 41, issue 2, pages 667-70. 10.1128/jcm.41.2.667-670.2003
71. Yücesoy M and others. Detection of toxin production in *Clostridium difficile* strains by three different methods. *Clin Microbiol Infect* 2002: volume 8, issue 7, pages 413-8. 10.1046/j.1469-0691.2002.00440.x
72. Vanpoucke H and others. Evaluation of six commercial assays for the rapid detection of *Clostridium difficile* toxin and/or antigen in stool specimens. *Clin Microbiol Infect* 2001: volume 7, issue 2, pages 55-64. 10.1046/j.1469-0691.2001.00141.x

73. Eastwood K and others. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for *C. difficile* tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. *J Clin Microbiol* 2009: volume 47, issue 10, pages 3211-7. 10.1128/jcm.01082-09
74. Liesenfeld O and others. Detection of *Clostridium difficile* toxin by enzyme immunoassay, tissue culture test and culture. *Infection* 1994: volume 22, issue 1, pages 29-32. 10.1007/bf01780761
75. Brazier JS. Role of the laboratory in investigations of *Clostridium difficile* diarrhea. *Clin Infect Dis* 1993: volume 16 Suppl 4, pages S228-33. 10.1093/clinids/16.supplement_4.s228
76. Whitehead SJ and others. Is there any value in measuring faecal calprotectin in *Clostridium difficile* positive faecal samples? *Journal of medical microbiology* 2014: volume 63, issue 4, pages 590-3. <https://doi.org/10.1099/jmm.0.067389-0>
77. Stubbs SL and others. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. *J Clin Microbiol* 1999: volume 37, issue 2, pages 461-3. 10.1128/jcm.37.2.461-463.1999
78. Eyre DW and others. WGS to determine the extent of *Clostridioides difficile* transmission in a high incidence setting in North Wales in 2015. *Journal of Antimicrobial Chemotherapy* 2018: volume 74, issue 4, pages 1092-100. 10.1093/jac/dky523
79. Eyre DW and others. Comparison of multilocus variable-number tandem-repeat analysis and whole-genome sequencing for investigation of *Clostridium difficile* transmission. *J Clin Microbiol* 2013: volume 51, issue 12, pages 4141-9. 10.1128/jcm.01095-13
80. Lloyd CD and others. Direct *Clostridioides difficile* ribotyping from stool using capillary electrophoresis. *Diagnostic Microbiology and Infectious Disease* 2021: volume 99, issue 3, pages 115259. <https://doi.org/10.1016/j.diagmicrobio.2020.115259>
81. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive 2023. pages 1-39. ++
82. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets 2000. ++
83. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 2005. pages 1-14. ++

84. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012: volume 61, pages 1-102.+
85. Department for Transport and others. Transport of infectious substances UN2814, UN2900 and UN3373 Guidance note number 17/2012 (revision 7). 2013. ++
86. Department of Health. Health Protection Legislation (England) Guidance. pages 1-112. 2010. ++
87. Gizzie N, Adukwu E. Evaluation of Liquid-Based Swab Transport Systems against the New Approved CLSI M40-A2 Standard. J Clin Microbiol 2016: volume 54, issue 4, pages 1152-6.2+ 10.1128/JCM.03337-15
88. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 2009. ++
89. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance L5 (sixth edition). HSE Books. 2013. ++
90. Health and Safety Executive. Risk assessment: A brief guide to controlling risks in the workplace. HSE. 2014. ++
91. Health and Safety Executive, Advisory Committee on Dangerous Pathogens. Management and operation of microbiological containment laboratories. HSE. 2019. ++
92. Health Services Advisory Committee. Safe working and the prevention of infection in clinical laboratories and similar facilities. Books. H 2003. ++
93. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967. ++
94. Home Office. Anti-terrorism, Crime and Security Act. 2001. ++
95. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. pages 1-37. ++
96. Scottish Government. Public Health (Scotland) Act. 2008. ++
97. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010. ++
98. UK Health Security Agency (UKHSA). Laboratory reporting to UKHSA: a guide for diagnostic laboratories. UKHSA 2023. pages 1-31. ++

99. The Royal College of Pathologists. The retention and storage of pathological records and specimens (5th edition). pages 1-59. 2015. ++
100. Tyrrell KL and others. Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability. J Clin Microbiol 2016: volume 54, issue 5, pages 1364-7.2+
10.1128/JCM.03246-15
101. World Health Organization. Guidance on regulations for the transport of infectious substances 2021-2022. WHO. 2021. ++
102. Viprey VF and others. A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018. Euro Surveill 2022: volume 27, issue 26. 10.2807/1560-7917.Es.2022.27.26.2100704
103. Huletsky A and others. Comparison of rectal swabs and fecal samples for the detection of Clostridioides difficile infections with a new in-house PCR assay. Microbiol Spectr 2024: volume 12, issue 6, pages e0022524.
10.1128/spectrum.00225-24
104. Skyum F and others. Evaluation of a new fast in-house Real-Time PCR assay for detecting both Norovirus and toxigenic *Clostridium difficile* using fecal sample and rectal swab. American Journal of Infection Control 2022: volume 50, issue 1, pages 67-71. 10.1016/j.ajic.2021.08.026
105. Kotar T and others. Evaluation of rectal swab use for the determination of enteric pathogens: a prospective study of diarrhoea in adults. Clin Microbiol Infect 2019: volume 25, issue 6, pages 733-8. 10.1016/j.cmi.2018.09.026
106. Freeman J, Wilcox MH. The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol 2003: volume 56, issue 2, pages 126-8.
10.1136/jcp.56.2.126
107. Brazier JS, Duerden BI. Guidelines for optimal surveillance of Clostridium difficile infection in hospitals. Commun Dis Public Health 1998: volume 1, issue 4, pages 229-30.
108. Nho SW and others. Pragmatic Strategy for Fecal Specimen Storage and the Corresponding Test Methods for Clostridioides difficile Diagnosis. Pathogens 2021: volume 10, issue 8. 10.3390/pathogens10081049
109. Murad YM and others. False Negative Results in Clostridium difficile Testing. BMC Infectious Diseases 2016: volume 16, issue 1, pages 430.
10.1186/s12879-016-1741-6

110. Fekety R and others. Treatment of antibiotic-associated *Clostridium difficile* colitis with oral vancomycin: comparison of two dosage regimens. *Am J Med* 1989: volume 86, issue 1, pages 15-9. 10.1016/0002-9343(89)90223-4
111. Zar FA and others. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007: volume 45, issue 3, pages 302-7. 10.1086/519265
112. Wensch C and others. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 1996: volume 22, issue 5, pages 813-8. 10.1093/clinids/22.5.813
113. Darkoh C and others. Novel one-step method for detection and isolation of active-toxin-producing *Clostridium difficile* strains directly from stool samples. *J Clin Microbiol* 2011: volume 49, issue 12, pages 4219-24. 10.1128/jcm.01033-11

UNDER CONSULTATION